Australian pharma company De Motu Cordis (DMC), which is developing an epinephrine DPI for the treatment of anaphylaxis, announced that it has contracted with Catalent for product assembly, expanding a November 2022 deal with the CDMO that covered formulation and manufacturing. The extension of the deal will provide manufacturing and assembly services through a … [Read more...] about De Motu Cordis announces expansion of deal with Catalent for services related to development of DMC-IH1 epinephrine DPI
Business
Merz Therapeutics acquires Inbrija levodopa DPI from Acorda
Merz Therapeutics announced that it has acquired Inbrija inhaled dry powder levodopa from Acorda Therapeutics, which declared bankruptcy earlier this year. Merz had served as a "stalking horse bidder" for the Acorda assets, which also included Fampyra. Inbrija has been approved treatment of OFF episodes in Parkinson’s disease patients since December 2018 in the US … [Read more...] about Merz Therapeutics acquires Inbrija levodopa DPI from Acorda
Vistagen gets additional patents covering PH80 pherine nasal spray for the treatment of migraine
Vistagen announced that it has been granted patents related to the use of PH80 pherine nasal spray for the treatment of migraine in Australia, Hong Kong, Japan, and Mexico. All four of the new patents should cover PH80 through 2040. The USPTO granted a patent covering the use of PH80 for migraine in 2022, and the EPO followed in 2023. PH80 intranasal … [Read more...] about Vistagen gets additional patents covering PH80 pherine nasal spray for the treatment of migraine
Ritedose increases production capacity for inhalation products
CDMO Ritedose Corporation announced that it has added blow-fill-seal (BFS) capacity to its manufacturing facility in Columbia, SC, USA that will allow it to manufacture an additional 180 million unit doses of opthalmic and respiratory solutions. In addition to contract development and manufacturing, Ritedose manufactures its own generic inhalation solutions, including … [Read more...] about Ritedose increases production capacity for inhalation products
Ethris announces $5 million in funding from the Gates Foundation and additional €3 million from Cipla to support continued development of ETH47 inhaled mRNA therapy
Ethris announced that the Gates Foundation is providing $5 million, and Cipla is investing an additional €3 million, that will be used to prepare for Phase 2 development of Ethris's ETH47 inhaled mRNA therapy. According to the company, the Gates Foundation funding "includes an equity investment component expected to close at the company’s next financing round." The … [Read more...] about Ethris announces $5 million in funding from the Gates Foundation and additional €3 million from Cipla to support continued development of ETH47 inhaled mRNA therapy
BARDA awards ~$40 million to CyanVac and ~$34 million to CastleVax for Phase 2b trials of intranasal COVID-19 vaccines
The Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services (HHS), announced that it has awarded approximately $40 million to CyanVac and approximately $34 million to CastleVax to support Phase 2b clinical trials of the companies' intranasal COVID-19 vaccine candidates. Each of the Phase 2b trials will … [Read more...] about BARDA awards ~$40 million to CyanVac and ~$34 million to CastleVax for Phase 2b trials of intranasal COVID-19 vaccines
Firebrick launches Nasodine nasal spray in Singapore
Firebrick Pharma, which recently launched its Nasodine povidone-iodine nasal spray in the US as a "nasal hygiene" product, has now announced the launch of Nasodine in Singapore as a germicidal product for protection against infection. As in the US, the nasal spray will now be available to consumers in Singapore via a web site, though Firebrick says that it may be able … [Read more...] about Firebrick launches Nasodine nasal spray in Singapore
Judge denies United Therapeutics bid to block launch of Liquidia’s Yutrepia treprostinil DPI
According to Liquidia Corporation, a judge in the US District Court for the District of Delaware has denied a United Therapeutics motion seeking a preliminary injunction to prevent Liquidia from launching Yutrepia treprostinil DPI for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). Earlier this year, the company said that … [Read more...] about Judge denies United Therapeutics bid to block launch of Liquidia’s Yutrepia treprostinil DPI
MannKind acquires Pulmatrix R&D facility and the companies cross-license inhalation technology
MannKind Corporation will assume the lease for a Pulmatrix research laboratory located in Bedford, MA, USA, and Pulmatrix will transfer the facility, including all laboratory equipment, to MannKind, the companies said. MannKind says that it plans to hire some of the Pulmatrix personnel who have been working at the lab. In addition, MannKind will acquire the rights … [Read more...] about MannKind acquires Pulmatrix R&D facility and the companies cross-license inhalation technology
Ferrer gets additional distribution rights to Tyvaso treprostinil inhalation solution
Ferrer has announced that its 2022 agreement with United Therapeutics for distribution rights to Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) outside of the US, Canada, Israel, Japan, and China has been modified to add two more indications: idiopathic pulmonary ibrosis (IPF) and … [Read more...] about Ferrer gets additional distribution rights to Tyvaso treprostinil inhalation solution